Whаt is the defining chаrаcteristic оf gymnоsperms?
GeneTech Sоlutiоns AG, а prоfitаble biophаrma company, has developed a breakthrough gene therapy treatment for sickle cell disease. The therapy will require €200 million to build a specialized manufacturing facility and launch commercially. The company's clinical team has extensive Phase III trial data from 450 patients showing the therapy achieves complete remission in 72% of patients with a single treatment, far exceeding existing therapies, but these results have not yet been made public (data embargo until FDA submission). The company is considering two financing options: Option 1: Issue new shares to raise €200 million (diluting existing shareholders by 20%) Option 2: Issue €200 million in bonds at 6% interest rate Management knows the gene therapy will likely generate €50 million in annual profits once approved and launched, but the market is uncertain about the therapy's commercial potential. Which statement is correct?